Navigation Links
The Ensign Group Expands into Colorado
Date:2/3/2009

DENVER, Feb. 3 /PRNewswire-FirstCall/ -- The Ensign Group, Inc. (Nasdaq: ENSG), announced today that it has expanded into Colorado by acquiring four long-term care facilities in the Denver metropolitan area. The facilities include Littleton Manor, a 35-bed skilled nursing facility in Littleton, Arvada Nursing Center, a 54-bed skilled nursing facility in Arvada, Julia Temple Center, a 128-bed skilled nursing facility in Englewood, and Chateau des Mons, a 48-bed assisted living facility in Englewood. The transfer was effective February 1, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )

"We are excited to extend our growing footprint into Colorado, and look forward to being a solid contributor to the Denver area's vibrant healthcare community," said Christopher Christensen, Ensign's President and Chief Executive Officer. Noting that all four facilities have outstanding clinical histories, stable long-term staffs and excellent reputations in their communities, he called them "the perfect platform for establishing Ensign's presence" in Colorado.

Ensign expects the newly-acquired facilities, which had a combined occupancy rate of approximately 86% at acquisition, to be accretive to earnings in 2009.

Ensign purchased the facilities from a not-for-profit corporation which had owned and operated them since 1990. Even though it was not the high bidder, Ensign was selected because its patient-centered operating philosophy most closely matched the seller's, according to a spokesman for the seller. "We are pleased that the former owner would entrust its legacy of excellence to us, and we expect to grow and enhance that legacy," said Mr. Christensen.

The flagship of the group, Julia Temple Center, was founded in 1921 as a residential treatment center for tuberculosis patients by Ms. Julia Temple, a nurse at nearby Swedish Hospital. Over time the Center grew and broadened its service offerings, becoming Colorado's first dedicated Alzheimer's care facility. The original facility was replaced by a new building in 1963, which has undergone several updates since then. Ensign is planning additional renovations, and also plans to continue serving Julia Temple Center's unique resident base.

Mr. Christensen reconfirmed that Ensign is actively seeking additional opportunities to acquire both well-performing and struggling long-term care operations across the Western United States. The Colorado acquisitions bring Ensign's growing portfolio to 69 facilities, 37 of which are Ensign-owned. Ensign affiliates hold purchase options on nine of the 32 leased facilities.

About Ensign(TM)

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and assisted living services, physical, occupational and speech therapies, and other rehabilitative and healthcare services for both long-term residents and short-stay rehabilitation patients at 69 facilities in California, Arizona, Texas, Washington, Utah, Idaho and Colorado. More information about Ensign is available at http://www.ensigngroup.net.


'/>"/>
SOURCE The Ensign Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Ensign Group Acquires Texas Skilled Nursing Facility
2. The Ensign Group Acquires California Skilled Nursing Facility
3. The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility
4. The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program
5. The Ensign Group to Present at the Oppenheimer 19th Annual Healthcare Conference
6. The Ensign Group, Inc. Reports Third Quarter 2008 Earnings; Reaffirms 2008 Guidance
7. The Ensign Group, Inc. Acquires Four Skilled Nursing Facilities
8. The Ensign Group Schedules 2008 Third Quarter Earnings Call for Friday, October 31, 2008
9. The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance
10. The Ensign Group Schedules 2008 Second Quarter Earnings Call for Thursday, August 7, 2008
11. The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds ... the launch of a new DRTV campaign with Belly Bands. , Having a dog ... from sprays to puppy pads and find nothing works, get Belly Bands, the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology: